The Online Investor
Diagnostics IPOs image Diagnostics IPOs » By The Online Investor Staff, updated Tue., Dec. 6, 9:38 AM
Recent initial public offerings in the Diagnostics IPOs category.

Slide #1. Fulgent Genetics Initial Public Offering

Company: Fulgent Genetics
Proposed Symbol: FLGT
Shares Offered: 4,200,000
Price Per Share: $9.00
Over-Allotment: 630,000
Description: Fulgent Genetics announced today the pricing of its initial public offering of 4,200,000 shares of its common stock at a public offering price of $9.00 per share, before underwriting discounts and commissions. Fulgent Genetics has granted the underwriters a 30-day option to purchase up to an additional 630,000 shares from the company at the same price. The shares are expected to begin trading on The NASDAQ Global Market on September 29, 2016, under the ticker symbol "FLGT." The offering is expected to close on October 4, 2016, subject to customary closing conditions.

IPOs: Fulgent Genetics

List of Diagnostics IPOs in this Slideshow: Company Ticker IPO Date Invitae Corporation NVTA Teladoc TDOC Fulgent Genetics FLGT

Diagnostics IPOs Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.